Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The clinical physiology of side effects in long-term L-DOPA therapy.

× No keyword cloud information.

26 in total

1. The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil.

Authors: W Birkmayer; P Riederer; M B Youdim; W Linauer
Journal: J Neural Transm Date: 1975 Impact factor: 3.575

2. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease.

Authors: M Yamamoto; M Yokochi; S Kuno; Y Hattori; Y Tsukamoto; H Narabayashi; H Tohgi; Y Mizuno; H Kowa; N Yanagisawa; I Kanazawa
Journal: J Neural Transm (Vienna) Date: 1997 Impact factor: 3.575

3. Brain-noradrenaline and 3-methoxy-4-hydroxyphenylglycol in Parkinson's syndrome.

Authors: P Riederer; W Birkmayer; D Seemann; S Wuketich
Journal: J Neural Transm Date: 1977 Impact factor: 3.575

Review 4. Emerging regenerative medicine and tissue engineering strategies for Parkinson's disease.

Authors: James P Harris; Justin C Burrell; Laura A Struzyna; H Isaac Chen; Mijail D Serruya; John A Wolf; John E Duda; D Kacy Cullen
Journal: NPJ Parkinsons Dis Date: 2020-01-08

5. The alpha2-adrenoceptor antagonist atipamezole reduces the development and expression of d-amphetamine-induced behavioural sensitization.

Authors: Juuso Juhila; Antti Haapalinna; Jouni Sirviö; Jukka Sallinen; Aapo Honkanen; Esa R Korpi; Mika Scheinin
Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2003-02-14 Impact factor: 3.000

The clinical physiology of side effects in long-term L-DOPA therapy.

1. The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil.

2. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease.

3. Brain-noradrenaline and 3-methoxy-4-hydroxyphenylglycol in Parkinson's syndrome.

Review 4. Emerging regenerative medicine and tissue engineering strategies for Parkinson's disease.

5. The alpha2-adrenoceptor antagonist atipamezole reduces the development and expression of d-amphetamine-induced behavioural sensitization.

6. "On-off" phenomenon in Parkinson's disease: correlation to the concentration of dopa in plasma.

Review 7. The pharmacology of Parkinson's disease: basic aspects and recent advances.

Review 8. Long term motor complications of levodopa: clinical features, mechanisms, and management strategies.

9. Recent observations on the clinical pharmacology of (-)deprenyl.

10. Intestinal absorption of levodopa in man.